Level Four Advisory Services LLC decreased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 131,392 shares of the biopharmaceutical company’s stock after selling 879 shares during the period. Level Four Advisory Services LLC’s holdings in Pfizer were worth $4,493,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in PFE. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC boosted its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares in the last quarter. 70.10% of the stock is currently owned by institutional investors.

Pfizer, Inc. (NYSE:PFE) traded down 0.51% during midday trading on Friday, reaching $33.25. 12,928,473 shares of the company’s stock were exchanged. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The firm has a market capitalization of $198.43 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00. The firm’s 50 day moving average is $33.40 and its 200 day moving average is $33.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is 94.12%.

TRADEMARK VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/pfizer-inc-pfe-position-cut-by-level-four-advisory-services-llc.html.

Several equities analysts have issued reports on PFE shares. Sanford C. Bernstein restated a “buy” rating and set a $35.00 target price on shares of Pfizer in a research note on Monday, April 24th. BMO Capital Markets restated a “hold” rating and set a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Barclays PLC restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Citigroup Inc. cut shares of Pfizer from a “neutral” rating to a “sell” rating and lowered their target price for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.